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Abstract  
Natural antibodies have been found to have anti-tumorigenic function. This study was 
designed to investigate whether natural IgG antibodies against vascular endothelial 
growth factor receptor 1 (VEGFR1) could suppress the growth of 
hepatocellular carcinoma (HCC) cells. Three HCC cell lines and A549 lung cancer 
cells were used for this study. They were grown, respectively, with human plasma 
positive or negative for anti-VEGFR1 IgG. Cell viability, apoptosis and VEGFR1 
gene expression were examined. Three patients with HCC were recruited for a case 
study. The results showed that plasma anti-VEGFR1 IgG significantly inhibited the 
proliferation of all three HCC cell lines but not A549 cell line; the proportions of 
apoptotic cells were significantly higher in HCC cells treated with anti-VEGFR1 IgG 
positive plasma than those treated with IgG negative plasma. The expression of the 
VEGFR1 gene was significantly higher in HCC cells than A549 cells. Of three HCC 
patients who received transfusion of anti-VEGFR1 IgG positive plasma, two cases 
with stage B showed a good response to the treatment but one with distant metastasis 
did not. Human plasma IgG against VEGFR1 may be a promising agent for anti-HCC 
therapy.  
Keywords: Hepatocellular carcinoma; VEGFR1; gene expression; natural antibody; 
tumor immunity; immunotherapy 
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Introduction 
Liver cancer is one of the most commonly diagnosed malignant tumors worldwide, 
which is the second leading cause of cancer-related deaths in men and the sixth 
leading cause in women [1] although it has become the third leading cause of female 
cancer deaths in China [2,3]. A recent epidemiological study demonstrated that during 
2012 there were about 782,500 new cases diagnosed as having liver cancer and 
745,500 deaths in the world, with China alone accounting for about 50% of the total 
number of cases and deaths [1]. Of all cases with liver cancer, more than 90% suffer 
from hepatocellular carcinoma (HCC) and the number of deaths due to HCC is 
dramatically increasing each year, with a 5-year survival rate of less than 9% [4,5]. 
Patients with late-stage HCC usually have a poor prognosis, and only 30-40 % are 
deemed to be eligible for curative intention with routine treatments, including surgical 
operation, radiotherapy, chemotherapy and liver transplantation [6,7]. With advances 
in surgical techniques and instrumentation as well as the development of molecular 
target drugs, several potentially curative treatments have become available [8-10], 
while postoperative therapies for preventing recurrence of HCC remain a key issue to 
enhance the survival of HCC patients.  
Tumor cells have the capability to produce some angiogenic factors such as 
vascular endothelial growth factors (VEGFs), which can bind to their corresponding 
receptors on the surfaces of cells, resulting in a variety of biological effects and 
thereby promoting tumor progression [11]. Accordingly, antiangiogenic therapy has 
been one of the main anticancer strategies. Bevacizumab (trade name Avastin) is a 
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humanized monoclonal antibody that inhibits the activity of vascular endothelial 
growth factor A (VEGF-A), and has been clinically used for the treatment of some 
metastatic cancers [12-14]. Interestingly, bevacizumab has also shown an inhibitory 
effect on the growth of human HCC both in vitro and in vivo [15], suggesting that 
HCC cells may express VEGF receptors. Despite its efficacy, systemic anticancer 
treatments with bevacizumab may have toxic effects on the cardiovascular system, 
promoting the development of hypertension, cardiac ischemia and congestive heart 
failure [16]. So there is an urgent need to develop alternative therapies to minimize 
the cardiovascular toxicity.  
Natural antibodies are likely to serve as an important anti-tumorigenic system in 
the body and their anti-tumor cytotoxicity has been confirmed with in vitro study 
[17,18]. It is possible that natural antibody-rich plasma from healthy donors could be 
used as postoperative therapies to prevent the recurrence of human cancer. In this 
study, therefore, we detected natural IgG antibodies against VEGF receptor 1 
(VEGFR1) in plasma and then analysed the effects of anti-VERGFR1 IgG rich plasma 
on the proliferation of HCC cell lines. We also recruited three patients with HCC for 
clinical trial with anti-VERGFR1 IgG rich plasma. 
 
Materials and methods 
Detection of anti-VEGFR1 IgG in plasma 
Plasma samples were collected from healthy blood donors by the Blood Center of 
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Dongguan, Guangdong Province, China and the Blood Center of Qingdao, Shandong 
Province, China. Pooled plasma of 20 randomly selected plasma samples was used as 
a reference sample (RS) for relative quantification of natural anti-VEGFR1 IgG levels 
in plasma. This work was approved by a local ethics committee based in Qingdao and 
conformed to the provisions of the Declaration of Helsinki.  
An enzyme-linked immune-sorbent assay (ELISA) was used to detect plasma IgG 
antibody against the extracellular domain of human VEGFR1 protein (NCBI 
accession NP_002010). The ELISA antibody test kit was supplied by Hailanshen 
Biotechnology Ltd, Qingdao, China, as described in our previous study [19]. In brief, 
the antigen-coated plate was washed twice with 200 μl Wash Buffer just before use; 
50 μl plasma sample diluted 1:200 in Assay Buffer was then added to each sample 
well, and 50 μl Assay Buffer was added to each negative control (NC) well. 
Following incubation at room temperature for 1.5 hours (hrs), the plate was washed 
three times with 200 μl Wash Buffer and 100 μl peroxidase-conjugated goat anti-human 
IgG antibody (ab98567, Abcam) diluted 1:30000 in Assay Buffer was added to each 
well. After incubation at room temperature for 1.5 hrs, color development was 
initiated by adding 50 μl Stabilized Chromogen (SB02, Life Technologies) and 
terminated 25 min later by adding 50 μl Stop Solution (SS04, Life Technologies). The 
measurement of optical density (OD) was completed on a microplate reader within 10 
min at 450 nm with a reference wavelength of 620 nm. All the samples were tested in 
duplicate and the specific binding ratio (SBR) was used to represent plasma 
anti-VEGFR1 IgG levels. Calculation of SBR is as follows:  
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SBR= (OD Sample – OD NC) / (OD RS – OD NC)  
 
Cell proliferation assay  
Three cell lines derived from human HCC, HepG2, BEL-7402 and BEL-7405 (China 
Academy of Chinese Medical Sciences, CACMS, China), were used for this study, 
and A549 cell line (CACMS, China) derived from lung cancer was used as control 
cells. These cancer cells were seeded in a 96-well plate, 100 μl/well with a density of 
2.5×104 cells/ml Dulbecco’s Modified Eagle Medium (DMEM, Gibco) containing 
10% fetal calf serum (FCS). After 24-hr incubation in humidified atmosphere with 5% 
CO2 at 37 oC, the medium was changed and cancer cells were cultured with DMEM 
containing 15% human plasma either positive or negative for anti-VEGFR1 IgG 
antibodies for 48 hrs in the same conditions as mentioned above. Cell counting kit-8 
(CCK-8, Sigma-Aldrich) was applied to detect cell viability. Briefly, 10 μl CCK-8 
solution was added to each well; after incubation at 37 oC for 2 hrs, OD of each well 
was measured on a microplate reader at 450nm wavelength. The complete medium 
was used as blank. Cell viability was used to present data and calculated as follows:  
Cell viability = (OD positive – OD blank) / (OD negative – OD blank).   
 
Analysis of apoptosis  
HCC cells were seeded in 6-well dishes, 2ml/well with a density of 2.5×105 cells/ml 
DMEM containing 10% FCS. After 24-hr incubation in humidified atmosphere with 
AJCR0050989. 2/21/17 Accepted. Original article 
5% CO2 at 37 oC, the medium was changed and HCC cells were cultured with DMEM 
containing 15% human plasma either positive or negative for anti-VEGFR1 IgG. 
Cultured cells were then collected at 24 hrs and 48 hrs, respectively, for analysis of 
apoptosis. 
Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, USA) was used to 
detect apoptosis of HCC cells according to the manufacturer’s instruction. Briefly, 
cultured cells were harvested, washed twice with cold PBS and re-suspended in 400 
μl Annexin V-FITC binding buffer. HCC cells were stained with 5 μl of Annexin 
V-FITC and incubated in the dark at 4 °C for 15 min; 10 μl propidium iodide (PI) was 
added to each well and incubated at 37 °C for 5 min. FACSCalibur flow cytometer 
(Becton–Dickinson, USA) was used to detect apoptosis of cells. 
VEGFR1 gene expression assay 
Both HCC and A549 cells were seeded in 6-well dishes, 2 ml/well with a density of 
2.5×105 cells/ml DMEM containing 10% FCS. After 48-hr incubation in humidified 
atmosphere with 5% CO2 at 37 oC, they were collected for extraction of total RNA 
using RNAiso reagent (TaKaRa Bio-technology, Dalian, China). Total RNA samples 
were treated with a DNA-free kit (Fermentas, Hanover, MD, USA) to eliminate DNA 
contamination, and then reversely transcribed into cDNA using PrimeScript™ RT 
Master Mix (TaKaRa Bio-technology). A cDNA aliquot equivalent to 40 ng of total 
RNA was used for quantitative real-time PCR (qRT-PCR) analysis, and SYBR 
Premix Ex Taq kit (TaKaRa Bio-technology) was used to quantify expression of the 
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VEGFR1 gene on the ABI 7500 real-time PCR system, with a pair of following 
primers: 5’-TTAGGACCAGGAAGCAGCAC-3’ (forward) and 
5’-CCGAGGTTCCTTGAACAGTGA-3’ (reverse). Glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) was used as a housekeeping gene for normalization, and 
GAPDH primers used for qRT-PCR amplification were purchased from QIAGEN 
(Shanghai, China). Relative quantity of gene expression was calculated using the 
comparative Ct method. Fold change (FC) was used to present data and worked out 
based on the formula: FC=2-ΔΔCt. 
Data analysis 
All experimental data were expressed as mean± standard deviation (SD). Student’s 
t-test (two-tailed) was applied to examine the differences in cell viability between 
cancer cells treated with anti-VEGFR1 IgG positive and negative plasma, in VEGFR1 
gene expression between HCC and A549 cells as well as in the percentage of 
apoptotic cells between HCC cells treated with anti-VEGFR1 IgG positive and 
negative plasma. 
Clinical case study 
Three HCC patients with history of hepatitis B and liver cirrhosis were recruited for 
treatment with anti-VEGFR1 IgG positive plasma; all three patients gave informed 
written consent to participate this clinical trial. Case one was male and diagnosed as 
having HCC with multiple nodules at the Second Hospital of Jilin University, 
Changchun in September 2014, and classified into stage B based on the Barcelona 
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Clinic Liver Cancer (BCLC) staging system [20]. This patient underwent 
segmentectomy of the liver, followed by chemoembolization treatment three times 
within a year. Recurrence was identified by intensive CT scan in October 2015, which 
showed multiple space-occupying lesions in the liver, although there was no sign of 
regional metastasis. He received the first transfusion of 950 ml anti-VEGFR1 IgG 
positive plasma at Dalang Hospital based in Dongguan on November 17-19, 2015. 
Case two was female and diagnosed as having HCC with intrahepatic metastasis at 
Affiliated Hospital of Qingdao University in June 2015, and classified into stage C 
based on the BCLC staging system. She received both radiotherapy and 
chemoembolization before HCC was confirmed to be progressing by PET-CT scan in 
August 2015; distant metastasis was found in the spleen in December 2016. This 
patient received the transfusion of 680 ml anti-VEGFR1 IgG positive plasma at the 
Central Hospital of Qingdao on March 8, 2016. Case three was male and diagnosed as 
having infiltrative HCC at the Sixth People’s Hospital of Qingdao in May 2016; this 
patient was classified into stage B based on the BCLC staging system and received 
treatment only with chemoembolization  twice since diagnosis was made. He 
received the first transfusion of 900 ml anti-VEGFR1 IgG positive plasma at the Sixth 
People’s Hospital of Qingdao on September 20-22, 2016. 
 
Results 
Plasma with the highest SBR value from two healthy donors was used as 
anti-VEGFR1 IgG positive plasma (A and B); anti-VEGFR1 IgG negative plasma was 
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taken from three healthy donors with the lowest SBR value and was mixed properly.  
Inhibitory effects of anti-VEGFR1 IgG plasma on proliferation of HCC cells 
As compared with anti-VEGFR1 IgG negative plasma, anti-VEGFR1 IgG positive 
plasma had capacity of significantly inhibiting the proliferation of BEL-7402 cells 
(t=-35.95, df=16, P<0.0001 for plasma A and t=-35.33, df=16, P<0.0001 for plasma 
B), BEL-7405 cells (t=-4.35, df=16, P=0.0005 for plasma B only) and HepG2 cells 
(t=-6.63, df=16, P<0.0001 for plasma A and t=-15.15, df=16, P<0.0001 for plasma B). 
However, anti-VEGFR1 IgG positive plasma did not show any inhibitory effect on 
the proliferation of A549 cells (Figure 1).  
Cell apoptosis induced by anti-VEGFR1 IgG plasma 
Based on the work on effects of anti-VEGFR1 IgG plasma on the proliferation of 
HCC cells (Figure 1), we used BEF-7402 and HepG2 cell lines to investigate their 
apoptosis induced by anti-VEGFR1 IgG positive plasma. As shown in Table 1, the 
proportion of apoptotic cells was significantly higher in HCC cells treated with 
anti-VEGFR1 IgG positive plasma (B) than those treated with anti-VEGFR1 IgG 
negative plasma (P<0.0001 for 24-hr treatment and P=0.0042 for 48-hr treatment in 
BEL-7402 cells; P=0.0003 for both 24-hr and 48-hr treatments in HepG2 cells). 
Expression of the VEGFR1 gene in BEL-7402, HepG2 and A549 cells  
Student’s t-test revealed that the levels of VEGFR1 gene expression were 
significantly higher in BEL-7402 (t=3.33, df=14, P=0.005) and HepG2 cells (t=5.60, 
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df=13, P<0.0001) than A549 cells, although HepG2 cells had the highest levels of 
VEGFR gene expression in these three cell lines (Figure 2). 
The outcomes of anti-VEGFR1 IgG positive plasma treatment 
The three patients with HCC received treatment with anti-VEGFR1 IgG positive 
plasma. Case one received plasma transfusion three times between November 2015 
and September 2016 (Table 2). The condition of this patient had been stable although 
intensive CT scan showed a nodule of ~10 mm (in diameter) in the segment-8 region, 
which was 8.7 mm (in diameter) measured in April 2015; this patient therefore 
received a treatment with radiofrequency ablation (RFA) on August 25, 2016, and 
also received the third transfusion of 720 ml anti-VEGFR1 IgG positive plasma at the 
Sixth People’s Hospital of Qingdao, China on September 9-12, 2016. However, a 
magnetic resonance imaging (MRI) scan identified at least 5 new nodules in the liver 
(segments 2, 3, 4, 6 and 8) on December 2, 2016, as compared to previous follow-up 
on September 9, 2016. While no further treatment was given, this patient was still 
alive based on the follow-up on February 15, 2017. Case two had progressed to a late 
stage of HCC before plasma transfusion was given; she died on April 28, 2016, with a 
survival of <12 months after first diagnosis was made. Case three had a follow-up 
examination with intensive CT scan on January 22, 2017 and remarkable 
improvement was observed by contrasting the CT scan image performed on 
September 7, 2016.  
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Discussion 
Natural antibodies are defined as the immunoglobulins produced by B lymphocytes in 
the absence of external antigen stimulation [18]. It has been proposed that the 
production of natural antibodies appears to be genetically controlled [21]. In function, 
natural antibodies are physiologically involved in maintaining tissue homeostasis such 
as elimination of invading pathogenic agents and non-functional proteins, clearance of 
apoptotic cells as well as destruction of cancer cells [17,18,22]. While IgM has been 
considered as the major isotype of natural antibodies, natural IgG isotype is also 
abundant in the circulation of most healthy individuals [19, 23].  
The present study demonstrated that some healthy individuals had remarkably 
high levels of natural IgG antibodies against VEGFR1, which could significantly 
inhibit the proliferation of HCC cells (Figure 1). Based on the observations from 
further study of apoptosis and gene expression in HCC cell lines (Table 1 and Figure 
2), anti-VEGFR1 IgG antibodies are likely to target the extracellular domain on the 
surfaces of HCC cells, inducing apoptosis of these malignant cells. To our knowledge, 
this is the first report on inhibitory effects of anti-VEGFR1 IgG antibodies on the 
proliferation of HCC cells in vitro.  
In this study, we also carried out clinical trials on three cases with HCC. Case one 
has been surviving with no apparent progression over a year since recurrence was 
confirmed in October 2015. However, plasma anti-VEGFR1 IgG failed to show a 
significant effect on survival of case two as splenic metastasis had been found before 
this HCC patient received plasma transfusion. Possibly, this therapy is not suitable for 
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the treatment of patients with late stage HCC. The infiltrative type of HCC accounts 
for 7-20% of all HCC cases worldwide [24] and a much higher proportion in China 
[25]. Patients with infiltrative type of HCC always have poor prognosis with low 
survival rates [24,25]. It is worth noting that plasma anti-VEGFR1 IgG appears to 
improve infiltrative HCC based on our study. We will continue to follow up cases one 
and three in order to draw a firm conclusion about the therapeutic effectiveness of 
anti-VEGFR1 IgG positive plasma on this malignancy. A large-scale clinical trial will 
be designed based on this initial study. 
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Table 1. Apoptosis induced by plasma anti-VEGFR1 IgG in HCC cells 
Time of cell 
treatment       
Percentage of apoptotic cells (%) 
T df P 
Negative plasma Positive plasma 
BEL-7402 
    24h 
 
3.192±0.315 
 
5.223±0.343 
 
10.70 
 
10 
 
<0.0001 
    48h 8.170±2.392 14.54±3.498 3.68 10 0.0042 
HepG2  
    24h 
 
2.275±0.816 
 
4.582±0.679 
 
5.33 
 
10 
 
0.0003 
    48h 2.570±0.359 5.153±1.096 5.49 10 0.0003 
Data were expressed as mean±SD. 
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Table 2. Clinical information of three HCC patients who received plasma transfusion 
 
Case Age 
(yrs) † 
Sex History 
of HB 
Liver 
cirrhosis 
Distant 
metastasis 
Plasma 
transfusion ‡ 
Outcome § 
One 68 M Yes 
 
Yes 
 
No Three times  PFS >12 
months  
Two 
 
60 F Yes Yes Yes Once Died 
Three 
 
66 
 
M 
 
Yes 
 
Yes 
 
Yes 
 
Once 
 
PFS >4 
months 
 
† Taken at the time of first hospitalization. 
‡ Case one received the second transfusion of 700 ml anti-VEGFR1 IgG positive 
plasma at Dalang Hospital based in Dongguan on April 19-21, 2016, and the third 
transfusion of 630 ml anti-VEGFR1 IgG positive plasma at the Sixth People’s 
Hospital of Qingdao on September 9-12, 2016.  
§ Case one had a progression-free survival (PFS) of >12 months based on an MRI scan 
that identified at least 5 new nodules in the liver on December 2, 2016. Case two died 
on April 28, 2016. The follow-up of case three was carried out on January 22, 2017 
and remarkable improvement was observed based on intensive CT scan.  
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Figure 1. Effects of plasma anti-VEGFR1 IgG on the proliferation of 4 cancer cell 
lines.  
Data of cell viability were expressed as mean±SD; ns: not significant 
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Figure 2. Expression of the VEGFR1 gene in BEL-7402, HepG2 and A549 cells  
Data of VEGFR1 gene expression were expressed as mean±SD. 
 
 
 
 
